A Randomized, Double-Blind 4-Week Study to Evaluate the Impact of AXS-05 on Smoking Behavior
Phase of Trial: Phase II
Latest Information Update: 12 Jun 2019
Price : $35 *
At a glance
- Drugs Bupropion/dextromethorphan (Primary) ; Bupropion
- Indications Smoking withdrawal
- Focus Therapeutic Use
- 08 Jun 2019 Status changed from active, no longer recruiting to completed.
- 15 Apr 2019 Primary endpoint has been met. (Change in Smoking Intensity), according to an Axsome Therapeutics media release.
- 15 Apr 2019 According to an Axsome Therapeutics media release, Duke University has completed topline analysis of the trial.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History